Abstract
The number of individuals afflicted by Alzheimer’s disease (AD) worldwide is rapidly rising and we, as a society, are approaching a critical junction in the development of new therapeutics aimed at slowing or preventing the onset of this devastating neurodegenerative disease. The prevailing theory in the field pinpoints the amyloid β peptide (Aβ) as the causal agent of the disease and thus strategies that target the production, deposition, and clearance of Aβ in the brain continue to be at the forefront of therapeutic interventions. Aβ is produced through a series of proteolytic cleavage events, with β-secretase (BACE1) being the rate-limiting enzymatic activity needed to begin the liberation of the Aβ peptide from the larger amyloid precursor protein (APP). As such, BACE1 itself has become a prime therapeutic target for AD. Still, over ten years after its discovery, only a handful of compounds targeting BACE1 have reached clinical trial, indicating that complex challenges continue to persist. This short review will focus on the cellular and molecular characteristics of BACE1, its role in APP processing and in AD, and its potential as a therapeutic target for AD.
Keywords: Alzheimer’s Disease, amyloid β-Peptide, β-Secretase, BACE1, therapeutics.
Current Enzyme Inhibition
Title:BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase
Volume: 9 Issue: 1
Author(s): Christopher J. Holler and Michael P. Murphy
Affiliation:
Keywords: Alzheimer’s Disease, amyloid β-Peptide, β-Secretase, BACE1, therapeutics.
Abstract: The number of individuals afflicted by Alzheimer’s disease (AD) worldwide is rapidly rising and we, as a society, are approaching a critical junction in the development of new therapeutics aimed at slowing or preventing the onset of this devastating neurodegenerative disease. The prevailing theory in the field pinpoints the amyloid β peptide (Aβ) as the causal agent of the disease and thus strategies that target the production, deposition, and clearance of Aβ in the brain continue to be at the forefront of therapeutic interventions. Aβ is produced through a series of proteolytic cleavage events, with β-secretase (BACE1) being the rate-limiting enzymatic activity needed to begin the liberation of the Aβ peptide from the larger amyloid precursor protein (APP). As such, BACE1 itself has become a prime therapeutic target for AD. Still, over ten years after its discovery, only a handful of compounds targeting BACE1 have reached clinical trial, indicating that complex challenges continue to persist. This short review will focus on the cellular and molecular characteristics of BACE1, its role in APP processing and in AD, and its potential as a therapeutic target for AD.
Export Options
About this article
Cite this article as:
J. Holler Christopher and P. Murphy Michael, BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer’s Disease Beta-Secretase, Current Enzyme Inhibition 2013; 9 (1) . https://dx.doi.org/10.2174/1573408011309010003
DOI https://dx.doi.org/10.2174/1573408011309010003 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine
Storm that Implicates for Therapeutic Strategies
Current Medicinal Chemistry Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
CNS & Neurological Disorders - Drug Targets Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Co-Occurrence of Large Cavum Septum Pellucidum and the Absence of the Adhesio Interthalamica in Patients with Schizophrenia: A Post Mortem Study
Current Psychopharmacology Role of Free Radicals and Poly(ADP-Ribose)Polymerase-1 in the Development of Spinal Cord Injury: New Potential Therapeutic Targets
Current Medicinal Chemistry The Effects of IGF-1 on Trk Expressing DRG Neurons with HIV-gp120- Induced Neurotoxicity
Current HIV Research Study on Utilization of Detoxified Jatropha curcas Seed Cake Subjected to Solid State Fermentation as a Dietary Supplement in Wistar Rats
Recent Patents on Food, Nutrition & Agriculture FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) Investigation of Image Processing Techniques in MRI Based Medical Image Analysis Methods and Validation Metrics for Brain Tumor
Current Medical Imaging Molecular Hydrogen as a Neuroprotective Agent
Current Neuropharmacology The Role of 18 kDa Mitochondrial Translocator Protein (TSPO) in Programmed Cell Death, and Effects of Steroids on TSPO Expression
Current Molecular Medicine A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Uncovering New Pharmacological Targets to Treat Neuropathic Pain by Understanding How the Organism Reacts to Nerve Injury
Current Pharmaceutical Design The Multiple Aspects of Stroke and Stem Cell Therapy
Current Molecular Medicine Subject Index to Volume 4
Current Molecular Medicine